z-logo
open-access-imgOpen Access
MicroRNA-200a Suppresses Cell Invasion and Migration by Directly Targeting GAB1 in Hepatocellular Carcinoma
Author(s) -
Jianlin Wang,
Wenjie Song,
Weiwei Sui,
Xisheng Yang,
Wei Sun,
Sshibin Qu,
Runze Shang,
Ben Ma,
Meng Pu,
Kaishan Tao,
Kefeng Dou,
Haimin Li
Publication year - 2017
Publication title -
oncology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.267
H-Index - 57
eISSN - 1555-3906
pISSN - 0965-0407
DOI - 10.3727/096504016x14685034103798
Subject(s) - cancer research , microrna , metastasis , carcinogenesis , downregulation and upregulation , biology , cell migration , cell , cancer , cell culture , hepatocellular carcinoma , cell growth , gene , genetics , biochemistry
MicroRNA-200a (miR-200a) is frequently downregulated in most cancer types and plays an important role in carcinogenesis and cancer progression. In this study, we determined that miR-200a was downregulated in hepatocellular carcinoma (HCC) tissues and cell lines, consistent with the results of our previous study. Because a previous study suggested that downregulation of miR-200a is correlated with HCC metastasis, we aimed to elucidate the mechanism underlying the role of miR-200a in metastasis in HCC. Here we observed that overexpression of miR-200a resulted in suppression of HCC metastatic ability, including HCC cell migration, invasion, and metastasis, in vitro and in vivo. Furthermore, bioinformatics and luciferase reporter assays indicated that GAB1 is a direct target of miR-200a. Inhibition of GAB1 resulted in substantially decreased cell invasion and migration similar to that observed with overexpression of miR-200a in HCC cell lines, whereas restoration of GAB1 partially rescued the inhibitory effects of miR-200a. Taken together, these data provide novel information for comprehending the tumor-suppressive role of miR-200a in HCC pathogenesis through inhibition of GAB1 translation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here